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originated (data not shown), one would perhaps expect 
to see mutations being lost or gained within the genes 
potentially affecting quinolone susceptibility. The 
stability of mutations in genes known to be associated 
with fluoroquinolone resistance, and the stable MIC 
values in clonally related MRSA isolates over time, have 
important implications for quinolone resistance in S. 
aureus. From this study of clinical MRSA isolates, it 
seems likely that once acquired, mutations and the 
decreased susceptibility to quinolones that they confer 
are highly stable, suggesting that the high prevalence of 
fluoroquinolone resistance that we are experiencing 
today in some parts of the world will remain. 
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Probiotics are microorganisms deliberately ingested to 
modify the gut flora in order to produce ‘health’ [l]. 
We report here what we believe to be the first case of 
endocarditis due to Lactobacillus rhau~nosus brought about 
by self-medication with a freeze-dried probiotic pre- 
paration, in a subject who was previously fit and well. 
Lactobacillus spp. are universally found in the mouth, 
female genital tract and gastrointestinal tract of humans, 
as well as in many foods and health food preparations. 
They are generally considered to be non-pathogenic 
[2,3]. Large quantities of products containing lactobacilli 
are sold worldwide; for example, 3 xlOh kg of products 
containing Lacfabacillus sp. GG (ATCC 53103) were 
sold in Finland alone in 1992 [2]. However, lactobacilli 
have been associated causally with endocarditis, menin- 
gitis, pneumonia and local suppurative conditions [4]. 
The case of endocarditis we report is also interesting 
since the source of the infecting bacteria in endocarditis 
is so rarely elucidated. (This case was presented as Poster 
M243 at The Second European Congress of Chemo- 
therapy, Hamburg, May 1998.) 
A 67-year-old male with previously documented 
mild mitral valve regurgitation due to mitral valve 
prolapse presented to his family doctor complaining of 
persistent dry cough, slight shortness of breath and 
weight loss. A few weeks earlier, some carious teeth had 
been removed, and 3 g of amoxycillin by mouth 1 h 
before the procedure was given as prophylaxis. The 
subject was taking one or two capsules daily of a freeze- 
dried probiotic preparation, each capsule of which was 
stated to contain 2 x lo9 L. rlzunzriorus and several other 
bacterial species (including L. acidophilus and Strepto- 
coccusfaecalis) to provide ‘a spectrum of friendly bacteria 
that inhabit the healthy gut’. As the subject had found 
the capsules too large to swallow, he was in the habit of 
emptying their contents into his mouth and chewing 
them with milk. 
The subject was referred to hospital; on examin- 
ation, he looked well. Old splinter hemorrhages were 
present on one hand. H e  was apyrexial, with blood 
pressure 140/90 mmHg and pulse 90/min in sinus 
rhythm. A loud pansystolic murmur of mitral valve 
regurgitation was present at the cardiac apex, radiating 
to his axilla. His lungs were clear and there were no 
signs of heart failure. The remainder of the examination 
was unremarkable. Results of laboratory tests were 
normal apart from low hemoglobin (111 g/L), and 
raised C-reactive protein (22 mg/L) and erythrocyte 
sedimentation rate (ESR) (52 mm/h). Chest X-ray and 
electrocardiogram were normal. A transthoracic echo- 
cardiogram showed moderate mitral valve regurgitation 
and increased tissue on the posterior mitral valve leaflet 
which was thought to be a small vegetation. 
Blood cultures yielded Gram-positive rods in all 
bottles of three sets. These grew in short chains on solid 
media after 48 h, and were catalase negative, aesculin 
positive and non-motile; further testing by API SOCHL 
and at The Public Health Laboratory showed the 
organisms to be L. rhamnosus. Eight further sets of 
blood cultures were also positive for L. rhamnosns. The 
antibiotic sensitivity was as shown in Table 1. One of 
the organisms cultured from the probiotic capsules was 
indistinguishable from that isolated from the blood 
cultures by virtue of identical cultural appearance, reac- 
tions in API 50CHL, sensitivity patterns and pyrolysis 
mass spectrometry. 
The patient was treated with intravenous ampicillin 
(2 g 8-hourly) +gentamicin (80 mg 12-hourly) for 2 
weeks and was discharged, well, on pivampicillin (1 g 
12-hourly) +probenecid (500 mg 6-hourly) for 6 weeks. 
Attempts to isolate the causal lactobacillus from the 
patient’s teeth or  bowel were unsuccessful. The patient 
was well at follow-up 3 months after admission. 
Although lactobacilli are recognized to be of low 
intrinsic virulence, there are several reports of infection 
caused by members of this genus. There are at least 58 
cases of endocarditis in the literature [5-81; SO% of 
these patients had some form of dental disease or had 
had dental treatment prior to the onset of endocarditis. 
Further, Antony et a1 [9] described 55 patients with 
lactobacillus bacteremia (often as part of a polybac- 
teremia) in the absence of endocarditis. In those cases 
where etiologic strains were speciated (unfortunately, 
this was often not done), it is clear that the great 
Table 1 Susceptibility pattern of Luctohacilltts rhamnosus (MICs in mg/L) 
Sensitive Intermediate Resistant 
Chloramphenicol (<4) 






Ampicillin (2) Cephaloridine (32) 
Benzylpenicillin (0.5) Co-trimoxazole (4/76a) 
Vancomycin (I  18) 
~~ 
Trimethoprim/sulfamethoxazole. 
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majority were the closely related, vancomycin-resistant 
[lo] species L. casei, L. paracasei or L. rhamnosus, and 
that the vancomycin-sensitive species L. acidophilus is 
only rarely implicated. 
Probiotics appear to be attractive to the public; 
promotional material makes such claims as ‘maintains a 
healthy digestion’, ‘improves digestibility and assimil- 
ation of food’, ‘keeps intestinal contents sweet’, ‘assists 
general well-being’, and ‘protects skin against harmfd 
microbes’. As, in the UK, probiotics are foods rather 
than medicines, ths type of claim, although virtually 
impossible to substantiate, is allowed. 
There is considerable evidence that lactobacilli may 
be tolerant to p-lactam antibiotics [6,11]; this may have 
led to the failure in the case reported here of the oral 
prophylaxu given before the dental treatment. Toler- 
ance has also been held responsible for treatment failure 
in several cases [6]. The patient described here chewed 
the contents of capsules, which could have increased 
the risk of endocarditis following dental treatment. 
Patients who are immunosuppressed or have pre- 
existing heart valve disease should avoid probiotic 
preparations containing L. rhamnosus, and warnings on 
packaging to this effect should be considered. It is 
noticeable that in the case presently being dscussed, it 
was the L. rhamnostrs rather than the other constituents 
of the probiotic capsules that caused the endocarditis, 
although all the species present had equal opportunity 
to colonize the valve. There appears to be less risk 
attached to the use of probiotic organisms such as 
L. acidophilur (see above) or Lactobacillus sp GG [2]. 
Another probiotic species best avoided is Enterococcus 
faecium (especially if vancomycin resistant [12]), as there 
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In the early 1990s, an increasing number of serogroup 
C meningococcal strains was observed [l], and a rise in 
the incidence of the disease was also found, especially 
in some regions in the northwest of the country, 
